

DAFTAR PUSTAKA

- Allredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson, P.A., Kradjan, W.A., dkk. (Editor), 2013. *Applied Therapeutics: The Clinical Use of Drugs*, 10th ed. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia.
- Ansari, S.F., Memon, M., Brohi, N., dan Tahir, A., 2019. N-acetylcysteine in the Management of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Cureus*, **11**: 2–7.
- Avdeev, S.N., Vizel, A.A., Abrosimov, V.N., Zaicev, A.A., Ignatova, G.L., Khamitov, R.F., dkk., 2020. Multicenter Double-Blind Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients with Chronic Obstructive Pulmonary Disease.
- Barnes, P.J., 2016. Inflammatory Mechanisms in Patients with Chronic Obstructive Pulmonary Disease. *Journal of Allergy and Clinical Immunology*, **138**: 16–27.
- Bhatt, S.P., Kim, Y., Harrington, K.F., Hokanson, J.E., Lutz, S.M., Cho, M.H., dkk., 2018. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. *Thorax*, **73**: 414–421.
- Calverley, P., Rogliani, P., dan Papi, A., 2021. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. *Drug Safety*, **44**: 273–290.
- Calzetta, L., Ritondo, B.L., Zappa, M.C., Manzetti, G.M., Perduno, A., Shute, J., dkk., 2022. The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. *European Respiratory Review*, **31**: 210196.
- Cazan, D., Klimek, L., Sperl, A., Plomer, M., dan Kölsch, S., 2018. Safety of Ambroxol in the Treatment of Airway Diseases in Adult Patients. *Expert Opinion on Drug Safety*, **17**: 1211–1224.
- Cazzola, M., Rogliani, P., Calzetta, L., Hanania, N.A., dan Matera, M.G., 2017. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **14**: 552–563.
- Chang, J.T., Meza, R., Levy, D.T., Arenberg, D., dan Jeon, J., 2021. Prediction of COPD risk accounting for time-varying smoking exposures. *PLOS ONE*, **16**: e0248535.

- Chen, Hong, Luo, X., Du, Y., He, C., Lu, Y., Shi, Z., dkk., 2023. Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013–2018. *BMC Pulmonary Medicine*, **23**: 318.
- Chen, Hengyi, Zhou, H., Luo, Chen, Zong, K., Fu, Y., Li, W., dkk., 2023. Efficacy of treatment with N-acetylcysteine inhalation for AECOPD: A propensity-score-matched cohort study. *The Clinical Respiratory Journal*, **17**: 1038–1047.
- Chisholm-Burns, M.A., Schwinghammer, T.L., Malone, P.M., Kolesar, J.M., Lee, K.C., dan Bookstaver, P.B., 2019. *Pharmacotherapy Principles and Practice, Fifth Edition*. McGraw-Hill, New York.
- Cho, P.S.P., Fletcher, H.V., Turner, R.D., Patel, I.S., Jolley, C.J., dan Birring, S.S., 2020. The Relationship Between Cough Reflex Sensitivity and Exacerbation Frequency in Chronic Obstructive Pulmonary Disease. *Lung*, **198**: 617–628.
- Cohen, J., Miles, M.C., Donohue, J., dan Ohar, J., 2016. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. *International Journal of Chronic Obstructive Pulmonary Disease*, 785.
- Crooks, M.G., Den Brinker, A.C., Thackray-Nocera, S., Van Dinther, R., Wright, C.E., dan Morice, A.H., 2021. Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations. *Lung*, **199**: 131–137.
- Dahlan, M.S., 2020. *Statistik Untuk Kedokteran Dan Kesehatan*, 6th ed. Epidemiologi Indonesia.
- De Backer, J., Vos, W., Van Holsbeke, C., Vinchurkar, S., Claes, R., Parizel, P., dkk., 2013. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. *International Journal of Chronic Obstructive Pulmonary Disease*, 569.
- Decalmer, S.C., Webster, D., Kelsall, A.A., McGuinness, K., Woodcock, A.A., dan Smith, J.A., 2007. Chronic cough: how do cough reflex sensitivity and subjective assessments correlate with objective cough counts during ambulatory monitoring? *Thorax*, **62**: 329–334.
- DiPiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D., dan Ellingrod, V. (Editor), 2020. *Pharmacotherapy: A Pathophysiologic Approach*, 11th ed. McGraw Hill Medical, New York.
- Fowdar, K., Chen, H., He, Z., Zhang, Jiujin, Zhong, X., Zhang, Jianquan, dkk., 2017. The effect of N-acetylcysteine on exacerbations of chronic

obstructive pulmonary disease: A meta-analysis and systematic review. *Heart & Lung*, **46**: 120–128.

Frye, R.E. dan Berk, M. (Editor), 2019. *The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine*. Springer, Singapore.

Ghobadi, H., Sadeghieh, S., Kameli, A., dan Lari, M., n.d. The Relationship between COPD Assessment Test (CAT) Scores and Severity of Airflow Obstruction in Stable COPD Patients.

GOLD, 2022. *Pocket Guide to COPD Diagnosis, Management, and Prevention a Guide for Health Care Professionals*. Global Initiative for Chronic Obstructive Lung Disease Inc, United State.

GOLD, 2023. *Global Strategy For the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2023 Report)*. Global Initiative for Chronic Obstructive Lung Disease Inc, United State.

Gupta, N., Pinto, L.M., Morogan, A., dan Bourbeau, J., 2014. The COPD Assessment Test: a Systematic Review. *European Respiratory Journal*, **44**: 873–884.

Hafiz, A.M.A.E., Wakeel, L.M.E., Hady, H.M.E., dan Mourad, A.E.R., 2013. High Dose N-acetylcysteine Improves Inflammatory Response and Outcome in Patients with COPD Exacerbations. *Egyptian Journal of Chest Diseases and Tuberculosis*, **62**: 51–57.

Han, M.K. dan Martinez, F.J., 2020. Host, Gender, and Early-Life Factors as Risks for Chronic Obstructive Pulmonary Disease. *Clinics in Chest Medicine*, **41**: 329–337.

Hsu, J., Stone, R., Logan-Sinclair, R., Worsdell, M., Busst, C., dan Chung, K., 1994. Coughing frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder. *European Respiratory Journal*, **7**: 1246–1253.

Huang, C., Kuo, S., Lin, L., dan Yang, Y., 2023. The efficacy of N -acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis. *Therapeutic Advances in Respiratory Disease*, **17**: 175346662311585.

Janjua, S., Pike, K.C., Carr, R., Coles, A., dan Fortescue, R., 2019. Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD). *Cochrane Database of Systematic Reviews*, .

Johnson, K., Niewoehner, D., McEvoy, C., Naqvi, S., Wendt, C., Reilkoff, R., dkk., 2016. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and

chronic bronchitis: a randomized, placebo-controlled trial. *International Journal of Chronic Obstructive Pulmonary Disease*, 799.

Jones, P.W., Harding, G., Berry, P., Wiklund, I., Chen, W.-H., dan Kline Leidy, N., 2009. Development and first validation of the COPD Assessment Test. *European Respiratory Journal*, **34**: 648–654.

Kantar, A., Klimek, L., Cazan, D., Sperl, A., Sent, U., dan Mesquita, M., 2020. An Overview of Efficacy and Safety of Ambroxol for the Treatment of Acute and Chronic Respiratory Diseases with a Special Regard to Children. *Multidisciplinary Respiratory Medicine*, **15**: 511.

Kemendes RI, 2013. *Riset Kesehatan Dasar*. Badan Penelitian dan Pengembangan Kementerian Kesehatan Republik Indonesia, Jakarta.

Kemendes RI, 2018. *Riset Kesehatan Dasar*. Badan Penelitian dan Pengembangan Kementerian Kesehatan Republik Indonesia, Jakarta.

Kepmenkes RI, 2019. *Tata Laksana Penyakit Paru Obstruktif Kronik*. Menteri Kesehatan Republik Indonesia, Jakarta.

Kim, S.-H., Park, J.-H., Lee, J.-K., Heo, E.Y., Kim, D.K., dan Chung, H.S., 2017. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. *Medicine*, **96**: e6826.

Ko, F.W., Chan, K.P., Hui, D.S., Goddard, J.R., Shaw, J.G., Reid, D.W., dkk., 2016. Acute exacerbation of COPD. *Respirology*, **21**: 1152–1165.

Kolarov, V., Stevuljevi, J.K., Ili, M., Bogdan, M., Tušek, B., Agic, A., dkk., 2022. Factorial Analysis of N-acetylcysteine and Propolis Treatment Effects on Symptoms, Life Quality and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled Trial. *European Review for Medical and Pharmacological Sciences*, .

Kosasih, A., Sutanto, Y.S., dan Susanto, A.D. (Editor), 2021. *Panduan Umum Praktek Klinis Penyakit Paru Dan Pernapasan*. Perhimpunan Dokter Paru Indonesia, Jakarta.

Kuzmenko, N., Iaremenko, O., Dobrianskiy, D., Ilnytskyi, R., dan Gumeniuk, G., 2020. The efficacy and safety of inhaled acetylcysteine in comparison with oral acetylcysteine in chronic obstructive pulmonary disease: A randomized single-center study. *Polish Annals of Medicine*, .

Kwon, J.-W., Moon, J.-Y., Kim, Sae-Hoon, Song, W.-J., Kim, M.-H., Kang, M.-G., dkk., 2017. Korean version of the Cough Symptom Score: clinical

utility and validity for chronic cough. *The Korean Journal of Internal Medicine*, **32**: 910–915.

Lemeshow, S., Hosmer, D.W., Klar, J., dan Lwanga, S.K. (Editor), 1990. *Adequacy of Sample Size in Health Studies*. Published on behalf of the World Health Organization by Wiley ; Distributed in the U.S.A., Canada, and Japan by Liss, England.

Lewis, A., Torvinen, S., Dekhuijzen, P.N.R., Chrystyn, H., Watson, A.T., Blackney, M., dkk., 2016. The Economic Burden of Asthma and Chronic Obstructive Pulmonary Disease and the Impact of Poor Inhalation Technique with Commonly Prescribed Dry Powder Inhalers in Three European Countries. *BMC Health Services Research*, **16**: 251.

Lexicomp, 2024. 'Facts and Comparisons Lexicomp Lexicomp For Dentistry', *Facts and Comparisons Lexicomp Lexicomp For Dentistry*. URL: <https://online.lexi.com/lco/action/home>.

Li, Q., 2019. Efficacy of Ambroxol Hydrochloride in the Treatment of Exacerbation of Chronic Obstructive Pulmonary Disease **26**: .

Li, Xueshan, Song, Q., Cheng, W., Liu, C., Lin, L., Li, J., dkk., 2023. The clinical characteristics and outcomes of different inhaled therapies in chronic obstructive pulmonary disease patients with frequent cough. *Annals of Medicine*, **55**: 2304107.

Loekito, B., 2014. 'Pengaruh Pemberian Erdosteine Pada Derajat Obstruksi Pasien Penyakit Paru Obstruktif Kronik Stabil', , *Tesis*, . Universitas Gadjah Mada, Yogyakarta.

Mahmoudinezhad, M., Abbaszadeh, F., Zarezadeh, M., Bahreini, N., Jamilian, Parsa, Jamilian, Parmida, dkk., 2023. N-acetylcysteine, a powerful agent in the reinforcement of anti-oxidant profile: A systematic review and dose-response meta-analysis of controlled clinical trials. *Clinical Nutrition ESPEN*, **54**: 227–238.

Malerba, M., Ponticiello, A., Radaeli, A., Bensi, G., dan Grassi, V., 2004. Effect of Twelve-months Therapy with Oral Ambroxol in Preventing Exacerbations in Patients with COPD. Double-blind, Randomized, Multicenter, Placebo-Controlled Study. *Pulmonary Pharmacology & Therapeutics*, **17**: 27–34.

Minov, J., Karadzinska-Bislimovska, J., Vasilevska, K., Stoleski, S., dan Mijakoski, D., 2015. Course of COPD Assessment Test (CAT) Scores During Bacterial Exacerbations of Chronic Obstructive Pulmonary Disease Treated in Outpatient Setting. *The Open Respiratory Medicine Journal*, **9**: 39–45.

- Miravittles, M., Koblizek, V., Esquinas, C., Milenkovic, B., Barczyk, A., Tkacova, R., dkk., 2019. Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study. *Respiratory Medicine*, **150**: 141–148.
- Miyazaki, M., Nakamura, H., Chubachi, S., Sasaki, M., Haraguchi, M., Yoshida, S., dkk., 2014. Analysis of comorbid factors that increase the COPD assessment test scores. *Respiratory Research*, **15**: 13.
- Mkorombindo, T. dan Dransfield, M.T., 2020. Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. *Clinics in Chest Medicine*, **41**: 475–484.
- Negro, R.W.D., Bonadiman, L., dan Turco, P., 2014. Sensitivity of the COPD assessment test (CAT questionnaire) investigated in a population of 681 consecutive patients referring to a lung clinic: the first Italian specific study.
- Ollier, C., Sent, U., Mesquita, M., dan Michel, M.C., 2020. Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan® Retard) Compared with Other Formulations in Healthy Volunteers. *Pulmonary Therapy*, **6**: 119–130.
- Papadopoulou, E., Hansel, J., Lazar, Z., Kostikas, K., Tryfon, S., Vestbo, J., dkk., 2023. Mucolytics for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: a Meta-analysis. *European Respiratory Review*, **32**: 220141.
- Papi, A., Avdeev, S., Calverley, P.M.A., Cordeiro, C.R., Jesenak, M., Koblížek, V., dkk., 2020. Use of mucolytics in COPD: A Delphi consensus study. *Respiratory Medicine*, **175**: 106190.
- Papi, A., Di Stefano, A.F.D., dan Radicioni, M., 2021. Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. *Advances in Therapy*, **38**: 468–478.
- Papi, A., Zheng, J., Criner, G.J., Fabbri, L.M., dan Calverley, P.M.A., 2019. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study. *Respiratory Medicine*, **147**: 37–43.
- Polkey, M., Vogelmeier, C., dan Dransfield, M., 2022. 'COPD Assessment Test', *COPD Assessment Test*. URL: www.CATestonline.org (diakses tanggal 28/3/2023).

Poole, P., Sathananthan, K., dan Fortescue, R., 2019. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, **2020**: .

PubChem, 2024a. 'Acetylcysteine', *Pubchem*. URL: <https://pubchem.ncbi.nlm.nih.gov/compound/Acetylcysteine#section=Cystal-Structures> (diakses tanggal 10/2/2024).

PubChem, 2024b. 'Ambroxol', *Pubchem*. URL: <https://pubchem.ncbi.nlm.nih.gov/compound/2132> (diakses tanggal 10/2/2024).

Rey-Brandariz, J., Pérez-Ríos, M., Ahluwalia, J.S., Beheshtian, K., Fernández-Villar, A., Represas-Represas, C., dkk., 2023. Tobacco Patterns and Risk of Chronic Obstructive Pulmonary Disease: Results From a Cross-Sectional Study. *Archivos de Bronconeumología*, **59**: 717–724.

Roberts, M.H., Clerisme-Beaty, E., Kozma, C.M., Paris, A., Slaton, T., dan Mapel, D.W., 2016. A Retrospective Analysis to Identify Predictors of COPD-related Rehospitalization. *BMC Pulmonary Medicine*, **16**: 68.

Sanguinetti, C.M., 2015. N-acetylcysteine in COPD: why, how, and when? *Multidisciplinary Respiratory Medicine*, **11**: 8.

Sari, C.P., Hanifah, S., Rosdiana, R., dan Anisa, Y., 2021. Efektivitas Pengobatan pada Pasien Penyakit Paru Obstruksi Kronis (PPOK) di Rumah Sakit Wilayah Yogyakarta. *Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, **11**: 215.

Shin, H.-J., Kim, Y.-I., Kim, Y., Lee, C.Y., Ra, S.W., Moon, J.-Y., dkk., 2023. When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD? *Chonnam Medical Journal*, **59**: 180.

Singh, D., Zhu, C.-Q., Sharma, S., Church, A., dan Kalberg, C.J., 2015. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: Results from a 4-week, randomized, crossover study. *Pulmonary Pharmacology & Therapeutics*, **31**: 85–91.

Stanford, R.H., Tabberer, M., Kosinski, M., Johnson, P.T., White, J., Carlyle, M., dkk., 2020. Assessment of the COPD Assessment Test Within U.S. Primary Care **7**: 26–37.

Sushko, V., Shvaiko, L., Bazyka, K., dan Riazhska, A., 2016. Treatment of Chronic Obstructive Pulmonary Disease in Clean Up Workers of the Chornobyl NPP Accident in the Remote Period After Irradiation with

Additional 6 Month Prescription Combination of Ambroxol and Essential Phospholipids **48**: .

- Tanimura, K., Sato, S., Fujita, Y., Yamamoto, Y., Hajiro, T., Horita, N., dkk., 2023. The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Chronic Respiratory Disease*, **20**: 147997312311660.
- Walia, G.K., Vellakkal, R., dan Gupta, V., 2016. Chronic Obstructive Pulmonary Disease and its Non-Smoking Risk Factors in India. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **13**: 251–261.
- Wang, C., Yan, J., dan Ma, C., 2023. Psychological distress and its associated factors among patients with chronic obstructive pulmonary disease in Hunan, China: a cross-sectional study. *Scientific Reports*, **13**: 5199.
- Wang, Z., Wang, M., Wen, S., Yu, L., dan Xu, X., 2019. Types and applications of cough-related questionnaires. *Journal of Thoracic Disease*, **11**: 4379–4388.
- Wells, B.G., DiPiro, J.T., Schwinghammer, T.L., dan DiPiro, C.V. (Editor), 2015. *Pharmacotherapy Handbook*, Ninth edition. ed. McGraw-Hill, New York.
- Willard, K.S., Sullivan, J.B., Thomashow, B.M., Jones, C.S., Fromer, L., Yawn, B.P., dkk., 2016. The 2nd National COPD Readmissions Summit and Beyond: From Theory to Implementation. *Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation*, **3**: 778–790.
- Zhan, W., Zhang, L., Jiang, M., Chen, M., Yuan, X., Sun, J., dkk., 2020. A new simple score of chronic cough: cough evaluation test. *BMC Pulmonary Medicine*, **20**: 68.
- Zhang, Y., Wang, L., Mutlu, G.M., dan Cai, H., 2021. More to Explore: Further Definition of Risk Factors for COPD – Differential Gender Difference, Modest Elevation in PM2.5, and e-Cigarette Use. *Frontiers in Physiology*, **12**: 669152.
- Zheng, L., 2021. The Effect of Adjuvant Therapy with Ambroxol Hydrochloride in Elderly Chronic Obstructive Pulmonary Disease Patients. *Am J Transl Res*, .